|
Active substance |
Entrectinib |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
adult and paediatric ≥ 12 years old patients, with NTRK fusion-positive, locally advanced or metastatic solid tumors |
|
Public documents |
|
|
Last update |
06/10/2021 |
Entrectinib
Last updated on 23/04/2024